
## Byoung Dae Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6821120/publications.pdf Version: 2024-02-01



RYOUNG DAF LEF

#	Article	IF	CITATIONS
1	Decoding the temporal nature of brain GR activity in the NFκB signal transition leading to depressive-like behavior. Molecular Psychiatry, 2021, 26, 5087-5096.	7.9	10
2	LRRK2 at the Crossroad of Aging and Parkinson's Disease. Genes, 2021, 12, 505.	2.4	17
3	PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease. Science Translational Medicine, 2021, 13, .	12.4	30
4	Pathological Functions of LRRK2 in Parkinson's Disease. Cells, 2020, 9, 2565.	4.1	44
5	High-Performance Conducting Polymer Nanotube-based Liquid-Ion Gated Field-Effect Transistor Aptasensor for Dopamine Exocytosis. Scientific Reports, 2020, 10, 3772.	3.3	29
6	Improved dynamic monitoring of transcriptional activity during longitudinal analysis in the mouse brain. Biology Open, 2019, 8, .	1.2	2
7	LRRK2 and membrane trafficking: nexus of Parkinson's disease. BMB Reports, 2019, 52, 533-539.	2.4	23
8	Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1635-1640.	7.1	70
9	Brain injury induces HIF-1α-dependent transcriptional activation of LRRK2 that exacerbates brain damage. Cell Death and Disease, 2018, 9, 1125.	6.3	39
10	Characterization of Parkinson's disease-related pathogenic TMEM230 mutants. Animal Cells and Systems, 2018, 22, 140-147.	2.2	4
11	Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration. Molecular Neurodegeneration, 2018, 13, 8.	10.8	87
12	Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology. ENeuro, 2017, 4, ENEURO.0004-17.2017.	1.9	31
13	Inflammatory signals induce the expression of tonicity-responsive enhancer binding protein (TonEBP) in microglia. Journal of Neuroimmunology, 2016, 295-296, 21-29.	2.3	19
14	Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond. BMB Reports, 2015, 48, 243-248.	2.4	36
15	Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration. Proceedings of the United States of America, 2015, 112, 11696-11701.	7.1	207
16	Poly (ADP-ribose) in the pathogenesis of Parkinson's disease. BMB Reports, 2014, 47, 424-432.	2.4	40
17	Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinson's Disease. Cell, 2014, 157, 472-485.	28.9	239
18	Microtubule-Targeting Agents Enter the Central Nervous System (CNS): Double-edged Swords for Treating CNS Injury and Disease. International Neurourology Journal, 2014, 18, 171.	1.2	13

BYOUNG DAE LEE

#	Article	IF	CITATION
19	Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nature Neuroscience, 2013, 16, 1392-1400.	14.8	182
20	Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. Trends in Pharmacological Sciences, 2012, 33, 365-373.	8.7	69
21	Measuring the Activity of Leucine-Rich Repeat Kinase 2: A Kinase Involved in Parkinson's Disease. Methods in Molecular Biology, 2012, 795, 45-54.	0.9	2
22	Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinson's Disease-Related Toxicity in Human Neurons. ACS Chemical Biology, 2011, 6, 1021-1028.	3.4	131
23	GSK3 controls axon growth via CLASP-mediated regulation of growth cone microtubules. Genes and Development, 2011, 25, 1968-1981.	5.9	134
24	Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Human Molecular Genetics, 2011, 20, 3933-3942.	2.9	120
25	Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nature Medicine, 2010, 16, 998-1000.	30.7	342